NKI researchers unravel drug resistance mechanism of melanoma


Patients with melanoma, an aggressive form of skin cancer, can benefit greatly from novel drugs like BRAF and MEK inhibitors. Unfortunately, almost all tumors develop resistance against these drugs over time. Judith Müller from the research team of Daniel Peeper at the Netherlands Cancer Institute (NKI) has unraveled a mechanism causing melanomas to display broad drug resistance, and also found how this type of resistance might be countered. Their work was published in Nature Communications on December 15. 

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.